Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Authorization Safety Study to Evaluate the Long-Term Safety and Tolerability of Vimpat® (Lacosamide) as Add-On Therapy in Epilepsy Patients With Partial-Onset Seizures Who Are Uncontrolled on Current Therapy

NCT00771927 is registered in ClinicalTrials.gov with UCB Pharma as lead sponsor.

NCT NCT00771927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00771927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Authorization Safety Study to Evaluate the Long-Term Safety and Tolerability of Vimpat® (Lacosamide) as Add-On Therapy in Epilepsy Patients With Partial-Onset Seizures Who Are Uncontrolled on Current Therapy
Lead sponsor
UCB Pharma
Phase
Observational
Overall status
Completed
Start date
October 31, 2008
Completion date
March 31, 2012
Enrollment
1,005 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

epilepsies, partial